Avectas
is a biotechnology company that develops and commercializes gene-modified cell therapy products for the treatment of cancer... Read moreAvectas
is a biotechnology company that develops and commercializes gene-modified cell therapy products for the treatment of cancer... Read more
News
Jun 15, 2026
Benzinga
Avectas: CCRM, OmniaBio and Avectas Partner to Improve Cell Therapy Manufacturing
Jan 16, 2023
Yahoo
Avectas: Avectas Launches the Solupore Platform for the Clinical Manufacturing of Next-Generation Gene-Modified Cell Therapies with Unparalleled Cell Health and Functionality
Nov 29, 2022
Yahoo
Avectas: Avectas, CCRM and OmniaBio Expand their Collaboration to Accelerate the Manufacture of Edited iPSCs Using SOLUPORE Technology
Oct 13, 2022
Pharamceutical Technology
Avectas: Inceptor Bio and Avectas partner for CAR-T cell therapies development
May 10, 2021
Markets Insider
Avectas: Avectas announces publication in leading cell therapy journal Cytotherapy of 'A novel non-viral delivery method that enables efficient engineering of primary human T cells for ex vivo cell therapy...
Apr 22, 2021
BioSpace
Avectas: AVECTAS Leads 7.23 million Consortium Awarded Part Funding From Disruptive Technologies Innovation Fund
Jan 11, 2021
Cision Canada
Press Release: Avectas : AVECTAS Appoints Daniel Castro as Chief Business Officer
Nov 05, 2020
Cision Canada
Press Release: Avectas : Avectas Opens Canadian Development Site
Jun 03, 2020
FinanzNachrichten
Avectas: Avectas and UC Davis Collaborate on Cell Engineering Technology
May 06, 2020
FinanzNachrichten
Avectas: Avectas and ONK Therapeutics to Develop Off-the-Shelf Cancer Therapy
